ArticleInternational journal of molecular sciences2025
SUL-150 Limits Vascular Remodeling and Ventricular Failure in Pulmonary Arterial Hypertension.
Lysanne M Jorna, Dalibor Nakládal, Johannes N van Heuveln, Diederik E van der Feen, Quint A J Hagdorn, Guido P L Bossers, Annemieke van Oosten, Michel Weij, Ludmila Tkáčiková, Soňa Tkáčiková and 4 more
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Lysanne M JornaDepartment of Pediatric and Congenital Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (CA40), 9713 GZ Groningen, The Netherlands.ORCID 0000-0002-3511-1988
Dalibor NakládalDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (AP50), 9713 GZ Groningen, The Netherlands.ORCID 0000-0003-0900-0130
Johannes N van HeuvelnDepartment of Experimental Pharmacology, Medical Faculty Mannheim, University of Heidelberg, Ludolf Krehlstrasse 13-17, 68167 Mannheim, Germany.
Diederik E van der FeenDepartment of Pediatric and Congenital Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (CA40), 9713 GZ Groningen, The Netherlands.
Quint A J HagdornDepartment of Pediatric and Congenital Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (CA40), 9713 GZ Groningen, The Netherlands.
Guido P L BossersDepartment of Pediatric and Congenital Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (CA40), 9713 GZ Groningen, The Netherlands.
Annemieke van OostenDepartment of Pediatric and Congenital Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (CA40), 9713 GZ Groningen, The Netherlands.
Michel WeijDepartment of Pediatric and Congenital Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (CA40), 9713 GZ Groningen, The Netherlands.
Ludmila TkáčikováDepartment of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy, Komenského 73, 041 81 Košice, Slovakia.
Soňa TkáčikováDepartment of Medical and Clinical Biophysics, Faculty of Medicine, Pavol Jozef Šafárik University, Trieda SNP 1, 040 11 Košice, Slovakia.ORCID 0000-0003-4457-7541
Robert H HenningDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (AP50), 9713 GZ Groningen, The Netherlands.ORCID 0000-0002-5135-4621
Martin C HarmsenLaboratory for Cardiovascular Regenerative Medicine, Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (EA11), 9713 GZ Groningen, The Netherlands.ORCID 0000-0002-7128-2741
Rolf M F BergerDepartment of Pediatric and Congenital Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (CA40), 9713 GZ Groningen, The Netherlands.ORCID 0000-0002-4385-5784
Guido KrenningLaboratory for Cardiovascular Regenerative Medicine, Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (EA11), 9713 GZ Groningen, The Netherlands.ORCID 0000-0001-5850-5667
Funding
Dutch Research Council 917.16.446NETHERLANDS CARDIOVASCULAR RESEARCH INITIATIVE (CVON) CVON Phaedra 2012-08
6 · The paper itself
Abstract
Pulmonary arterial hypertension (PAH) is a rare, progressive, and incurable disease characterized by an elevated pulmonary blood pressure, extensive remodeling of the pulmonary vasculature, increased pulmonary vascular resistance, and culminating in right ventricular failure. Mitochondrial dysfunction has a major role in the pathogenesis of PAH and secondary right ventricular failure, and its targeting may offer therapeutic benefit. In this study, we provide proof-of-concept for the use of the mitochondrially active drug SUL-150 to treat PAH. PAH was induced in rats by monocrotaline, followed by the placement of an aortocaval shunt one week later. The mitoprotective compound SUL-150 (~6 mg·kg
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SUL-150 Limits Vascular Remodeling and Ventricular Failure in Pulmonary Arterial Hypertension. · full record | OpenQuestion